Your Input Creates a Better Understanding of Immunoglobulin (Ig) Replacement Therapy
Last month, the IDF 2018 National Ig Treatment Experiences and Preferences Survey was mailed to select households. Co-developed with immunologists, the survey specifically focuses on patients’ experiences with intravenous immunoglobulin replacement therapy (IVIG) and subcutaneous immunoglobulin replacement therapy (SCIG).
If you misplaced the first packet that was mailed or did not have time to complete the survey a few weeks ago, don’t worry! A second packet was recently mailed, and you still have an opportunity to share your Ig treatment experience with IDF. IDF needs your help learning more about how Ig replacement therapy affect individuals’ lives and your participation will provide information that is vital to continuing the mission of IDF: to improve the diagnosis, treatment and quality of life of people with PI.
Results from our previous National Ig Treatment Experiences and Preferences Surveys, conducted in 1996, 2003, 2008 and 2013, have dramatically helped patients, families, healthcare providers and policy-makers to better understand how Ig replacement therapy impacts the lives of individuals with PI—one of those people may have been you. We encourage you to share your experiences with IDF and help others.
If you have any questions, please contact us: 800-296-4433 or email@example.com.
This article originally appeared in the IDF monthly e-newsletter, Primary Immune Tribune. Click here to subscribe.